The Cystic Fibrosis Foundation announced the launch of a first-of-its-kind Cystic Fibrosis Lung Transplant Consortium (CFLTC) Biorepository and Registry. The CFLTC Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will support research to improve understanding of the factors that affect lung transplant outcomes.
A particular focus of the registry will be the factors that contribute to chronic lung allograft dysfunction (CLAD), one of the most common post-transplant complications and a leading cause of death post-transplant.
The CFLTC Biorepository and Registry act like a library — the Registry stores clinical data related to transplant care and the Biorepository stores biological samples, including blood and bronchoalveolar lavage fluid. Researchers can access these samples and data to support research into CLAD to help improve short- and long-term transplant outcomes. Having a central and standardized approach will enable researchers to ask more precise questions and come to stronger conclusions.
Click here to read more.